Inventor · disambiguated record
Akin Akinc
Also filed as: AKINC AKIN
60 granted patents·54 pending applications·2,567 citations·filing 2003–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC59ARBUTUS BIOPHARMA CORP11GENZYME CORP8FITZGERALD KEVIN5TEKMIRA PHARMACEUTICALS CORP4
Top patents by PatentIndex Score
114 records- 0199US7605251B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Oct 20, 2009·160 cites·20 claims
- 0298US11679158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 20, 2023·7 cites·13 claims
- 0398US11633479B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·24 claims
- 0498US11633480B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·28 claims
- 0598US11612657B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·9 cites·30 claims
- 0698US11590229B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 28, 2023·11 cites·29 claims
- 0798US11382979B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 12, 2022·18 cites·30 claims
- 0898US11246933B1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 15, 2022·30 cites·28 claims
- 0998US10369226B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 6, 2019·25 cites·42 claims
- 1098US9061063B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jun 23, 2015·41 cites·32 claims
- 1198US9051567B2Methods for increasing efficacy of lipid formulated siRNAFITZGERALD KEVIN·Filed 2010·Granted Jun 9, 2015·104 cites·25 claims
- 1298US9012498B2Biodegradable lipids for the delivery of active agentsMANOHARAN MUTHIAH·Filed 2011·Granted Apr 21, 2015·104 cites·41 claims
- 1398US8642076B2Lipid containing formulationsMANOHARAN MUTHIAH·Filed 2011·Granted Feb 4, 2014·155 cites·28 claims
- 1498USRE43612EBiodegradable poly(β-amino esters) and uses thereofANDERSON DANIEL GRIFFITH·Filed 2009·Granted Aug 28, 2012·100 cites·69 claims
- 1598US7737265B2RNAi modulation of HIF-1 and therapeutic uses thereofALNYLAM PHARMACEUTICALS INC·Filed 2006·Granted Jun 15, 2010·122 cites·27 claims
- 1698US7427394B2Biodegradable poly(β-amino esters) and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2003·Granted Sep 23, 2008·172 cites·36 claims
- 1797US9682922B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 20, 2017·39 cites·18 claims
- 1897US9394234B2Lipid formulationsTEKMIRA PHARMACEUTICALS CORP·Filed 2014·Granted Jul 19, 2016·117 cites·10 claims
- 1997US8802644B2Lipid formulationCHEN JIANXIN·Filed 2012·Granted Aug 12, 2014·124 cites·35 claims
- 2097US8158601B2Lipid formulationCHEN JIANXIN·Filed 2010·Granted Apr 17, 2012·777 cites·30 claims
- 2196US11071784B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·5 cites·1 claims
- 2296US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 2396US8334373B2Nuclease resistant double-stranded ribonucleic acidVORNLOCHER HANS-PETER·Filed 2011·Granted Dec 18, 2012·30 cites·22 claims
- 2496US8273869B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2010·Granted Sep 25, 2012·17 cites·27 claims
- 2596US7928217B2Nuclease resistant double-stranded ribonucleic acidALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Apr 19, 2011·37 cites·19 claims
- 2695US11400158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Aug 2, 2022·1 cites·30 claims
- 2795US8598139B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2012·Granted Dec 3, 2013·15 cites·26 claims
- 2895US8324366B2Compositions and methods for delivering RNAI using lipoproteinsAKINC AKIN·Filed 2009·Granted Dec 4, 2012·33 cites·18 claims
- 2994US10934544B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·15 cites·23 claims
- 3094US10053689B2Methods for increasing efficacy of lipid formulated siRNAARBUTUS BIOPHARMA CORP·Filed 2015·Granted Aug 21, 2018·7 cites·9 claims
- 3194US8034376B2Lipid containing formulationsALNYLAM PHARAMACETICALS INC·Filed 2008·Granted Oct 11, 2011·71 cites·24 claims
- 3293US11208660B1Coronavirus iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 28, 2021·3 cites·30 claims
- 3393US9415109B2Stable non-aggregating nucleic acid lipid particle formulationsALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Aug 16, 2016·14 cites·29 claims
- 3492US12364762B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 22, 2025·0 cites·14 claims
- 3592US12350338B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 8, 2025·0 cites·14 claims
- 3692US12343398B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 1, 2025·0 cites·30 claims
- 3792US12239709B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 4, 2025·0 cites·28 claims
- 3892US8222222B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2009·Granted Jul 17, 2012·13 cites·27 claims
- 3992US8148344B2Compositions and methods for mediating RNAi in vivoAKINC AKIN·Filed 2009·Granted Apr 3, 2012·26 cites·25 claims
- 4092US2025171785A1Compositions and methods for inhibiting expression of the pcsk9 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4191US11420931B2Lipid containing formulationsARBUTUS BIOPHARMA CORP·Filed 2019·Granted Aug 23, 2022·2 cites·20 claims
- 4291US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 4391US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 4491US2024398956A1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4590US11091759B2Methods and compositions for treating a Serpinc1-associated disorderGENZYME CORP·Filed 2016·Granted Aug 17, 2021·31 cites·38 claims
- 4690US9687448B2Nucleic acid lipid particle formulationsALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Jun 27, 2017·7 cites·7 claims
- 4789US9260718B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 16, 2016·6 cites·27 claims
- 4889US8809292B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2012·Granted Aug 19, 2014·7 cites·38 claims
- 4988US8846631B2MicroRNA compositions and methodsMARCUSSON ERIC G·Filed 2011·Granted Sep 30, 2014·9 cites·15 claims
- 5088US2023256098A1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 114 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Akin Akinc files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →